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Summary. Preconditioning is an effective means of pro- 
tecting the heart against prolonged ischemia by pretreating 
it with a minor insult, and the present paper reviews various 
controversies in this highly active field of research. In many 
models, adenosine plays a role by triggering the activation 
of protein kinase C. It may work in conjunction with other 
agents, such as bradykinin, but the putative role of noradren- 
aline is uncertain. Regulation of the enzyme producing aden- 
osine (i.e., 5'-nncleotidase) has been reported during precon- 
ditioning but, because its activity does not seem to be 
associated with infarct size, it is unlikely that the hydrolase 
plays a pivotal role. Controversial data have been published 
on the involvement of mitochondrial ATPase, which may be 
ascribed to the poor time resolution of the experiments de- 
scribed; however, we do not believe that either acidosis or 
tissue ATP are important factors in triggering precondi- 
tioning. The role of glycolysis in the preconditioning effect 
remains to be firmly established; opposite mechanisms are 
activated in low-flow and stop-flow protocols. Although spe- 
cies differences regarding preconditioning exist, they seem 
to be more of a quantitative than a qualitative nature. The 
phenomenon could be clinically relevant because evidence is 
accumulating that preconditioning may take place during by- 
pass surgery and coronary angioplasty if longer balloon- 
occlusion times are used. 
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Ischemic preconditioning makes use of a mild stress 
in order to activate ndogenous defense mechanisms 
and so enable protection from further major stress. 
All of the protocols described in the literature lead to 
a first-time window of protection lasting 60-120 min- 
utes [62]. Originally, Murry et al. [32] used the limita- 
tion of infarct size as the criterion establishing the 
efficacy of an intervention, but subsequent studies 
have adapted a host of other variables to assess reduc- 
tion of cell damage, including contractile, morphologi- 
cal, electrophysiological, and biochemical parameters. 
This article reviews various controversies in this 
highly active field of research. 
Adenos ine  and  Catecho lamines  
In ischemic preconditioning, endogenous adenosine 
protects the heart by stimulating the adenosine A1- 
receptor. However, comparison between the cardio- 
protection induced by exogenous adenosine and that 
induced by preconditioning shows that discrepancies 
exist regarding the time frame [61] and extent of pro- 
tection [55]. Goto et al. [17] proposed that a threshold 
level of protein kinase C (PKC) stimulation must be 
reached before cardiac protection by ischemic precon- 
ditioning takes place (Fig. 1), and that adenosine and 
bradykinin released uring preconditioning could play 
major oles in triggering protection by stimulating the 
ldnase, provided that the activity exceeds the thresh- 
old [17]. Others have suggested that components such 
as norepinephrine [50] play a role in reaching the 
threshold, and Downey's group has reported that hyp- 
oxia also preconditions rabbit myocardium via adeno- 
sine and catecholamine release [8]. 
In line with this observation, ischemic precondi- 
tioning failed to limit infarct size in a study of rabbit 
hearts depleted of norepinephrine [49]. Using a simi- 
lar approach, Weselchouch et al. [58] found no evi- 
dence that catecholamines are involved in precon- 
ditioning in the rat model. In the same species, Hu 
and Nattel [20] reported that stimulation of ~l- 
adrenoceptors causes ischemic preconditioning, but 
recently Moolman et al. [31] have found no evidence 
of such a mechanism. In agreement with other obser- 
vations [44], our own data [12] show that short periods 
of ischemia, such as those used during precondi- 
tioning, do not lead to norepinephrine release into the 
effluent of isolated rabbit hearts. Furthermore, as re- 
ported recently by Seyfarth et al. [45], precondi- 
tioning suppresses norepinephrine release after a long 
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Fig. 1. Hypothetical threshold of protein kinase C (PKC) 
stimulation that must be reached before cardiac protection 
takes place by ischemic preconditioning (PC). One cycle of 
preconditioning produces ubstantial amounts of adenosine 
(Adeno) and bradykinin (Brady), in addition to norepineph- 
rine (Norepi), which is enough to simulate PKC. I f  the second 
component is absent due to bradykinin B2-receptor blockade 
with HOE 140, extra cycles are needed to produce enough ago- 
nist for PKC stimulation and preconditioning. (After Goto et 
al. [17], with permission.) 
ischemic period. These authors suggested that tran- 
sient ischemia may have a protective ffect on neural 
tissue by reducing norepinephrine-induced damage 
during extended periods of myocardial ischemia. We 
believe that this is a more likely mechanism than pro- 
tection induced by high catecholamine l vels. Taken 
together, these observations suggest that a combina- 
tion of agents mediate ischemic preconditioning, and 
further investigation is clearly needed to evaluate the 
potential interrelated actions of adenosine norepi- 
nephrine. 
Hydro lases  
5'-nucleotidase 
After investigating the relationship between adreno- 
ceptors and preconditioning, Kitakaze's group re- 
ported that 5'-nucleotidase activity increases during 
~l-adrenoceptor stimulation [26]; they also reported 
increases in 5'-nucleotidase and therefore adenosine 
production after preconditioning [25]. This latter find- 
ing conflicts with results obtained by other groups 
[12,39]. The older methodology used by Kitakaze et 
al. to measure phosphatase is aspecific and poorly doc- 
umented [25,26]; although Przyklenk et a1.[38] re- 
ported an increase in 5'-nucleotidase activity, they did 
not find any association with infarct size. It is thus 
unlikely that 5'-nucleotidase triggers preconditioning 
in the dog heart. 
Mitochondrial ATPase 
Within seconds after the onset of ischemia and the 
cessation of the electrochemical gradient across the 
inner mitochondrial membrane, the mitochondrial 
ATP-synthase changes into an ATPase (mF1Fo- 
ATPase). As reviewed by Rouslin [40], inhibition 
studies with oligomycin show that most of the ATP 
hydrolyzed uring global ischemia is due to mFIF o- 
ATPase activity. The binding of ATPase inhibitor 
(IF1) to the ATPase leads to reduced ATP hydrolysis. 
IF 1 is an unidirectional inhibitor whose binding is re- 
versible upon the resumption of oxidative metabolism. 
Protonic inhibition of the complex prevents ATP 
squandering by mF1Fo-ATPase activity in ischemic 
heart cells, probably by means of IF 1 binding. 
Various groups have examined whether ATPase in- 
hibition may explain the improved energy balance ob- 
served in preconditioned hearts [32]. In rat hearts 
perfused according to Langendorff, preconditioning 
induced greater ATPase inhibition and less high- 
energy phosphate depletion during sustained global 
ischemia [56]. However, Vander Heide et al. [52] con- 
cluded that altered mF1Fo-ATPase activity in region- 
ally ischemic dog hearts is not responsible for the en- 
ergy-sparing effect of ischemic preconditioning. These 
results are surprising because species with fast heart 
rates, such as the rat, have less IF1 inhibitor protein 
than those with slow heart rates, such as the dog [40]. 
However, we would like to point out that Vander 
Heide et al. [52] only measured ATPase activity after 
the last 5-minute reperfusion period of the precondi- 
tioning protocol, and so the possibility remains that 
the inhibition of ATPase in preconditioned hearts be- 
came faster or stronger during the sustained ischemic 
period in their study. 
Recent data complicate this issue even further. Ko- 
bara et al. [27] observed greater ATPase activity dur- 
ing global ischemia and reperfusion in isolated and 
preconditioned rat hearts than in controls. Further- 
more, the degree of ATP depletion during ischemia 
was no different between preconditioned and control 
hearts, whereas ATP levels recovered better during 
reperfusion in preconditioned hearts. The authors 
concluded that the preservation of ATPase (and ade- 
nine nucleotide translocase) activities may be respon- 
sible for the improved restoration of high-energy 
phosphates. 
Although a proper ATP level is crucial for cell ho- 
meostasis, it is dissociated from postischemic function 
[33]. We have no reason to believe that the concentra- 
tion of ATP is an important factor in eliciting precon- 
ditioning. 
Glycolysis 
The role of preconditioning in glycolysis/glycogenoly- 
sis during ischemia, as well as its relationship to is- 
chemic injury, is controversial. Anaerobic glycolysis 
supports cell function by means of ATP production, 
but accumulated glycolytic end products (lactate, 
sugar and triose phosphates, protons originating from 
ATP hydrolysis [33]) may determine the extent of 
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ischemic damage. Consequently, many studies have 
attempted to relate the beneficial effects of ischemic 
preconditioning to cardiac glycogen content or giyco- 
lytic rates. 
Low-flow ischemia 
Preconditioning before low-flow ischemia increases 
ischemic glycolytic flux and decreases cardiac injury 
[23]. These observations agree well with the results 
of studies howing that enhanced glycolysis and main- 
tained glycolytic ATP production by various means 
lead to reduced amage and improved function upon 
reperfusion [42,54]. During low-flow hypoxia in rat 
heart, glucose prevents the loss of sarcolemmal integ- 
rity and contractile function [30]. 
One may pose the question: Why does anaerobic 
glycolytic flux protect he myocardium subject o hyp- 
oxia/low-flow ischemia? The answer seems to be that 
the ATP derived from anaerobic glycolysis is prefer- 
entially used for membrane-ion pumps and the preser- 
vation of cell integrity. During moderate ischemia, an- 
aerobic glycolysis is stimulated (the Pasteur effect), 
whereas during severe ischemia, this effect is inhib- 
ited by the accumulation of lactate and protons, and 
glycolysis ceases [34]. During low-flow ischemia, lac- 
tate and protons are continuously washed out of the 
ischemic heart, thus preventing their accumulation i
tissue and the consequent inhibition of anaerobic gly- 
colysis. Therefore, if the accumulation of the poten- 
tially toxic products of glycolysis is prevented by sus- 
taining a moderate flow to the heart, glycolysis can 
be maintained and glycolytic ATP may preserve cell- 
membrane integrity and reduce Ca 2+ overload uring 
reperfusion. 
We believe that the maintenance ofglycolysis dur- 
ing low-flow ischemia prevents myocardial injury [34]. 
So far, only one study [23] has reported that ischemic 
preconditioning increases glycolytic flux and reduces 
ischemic ell damage. More research is necessary to 
clarify the important relationship between precondi- 
tioning and glycolysis during low-flow ischemia. 
Stop-flow ischemia 
Unlike low-flow ischemia, ischemic preconditioning 
causes a decrease in glycolytic flux during stop-flow 
global [41] and regional [32,59] ischemia in both iso- 
lated [41] and in vivo [32,59] models. Other strategies 
aiming at decreased glycolytic flux during regional 
stop-flow ischemia also induce less ischemic injury 
[18]. 
Several groups, including Wolfe et al. [59], assume 
that the beneficial effects of preconditioning are re- 
lated to the reduced lactate accumulation and proton 
production that are the result of lower glycolytic 
rates, despite reduced ATP production. However, 
Vander Heide et al. [51] dissociated glycogen deple- 
tion and the reduction in lactate accumulation and an- 
aerobic glycolytic flux from ischemic damage. Our own 
nuclear magnetic resonance (NMR) studies also dem- 
onstrate cardioprotection by preconditioning in iso- 
lated rat hearts without any effects on pH [6], leading 
us to believe that acidosis is not a key factor in either 
functional recovery or ischemic injury [41]. 
Ischemic preconditioning of the heart reduces its 
preischemic glycogen content. Wolfe et al. [59] corre- 
lated the decrease in infarct size caused by precondi- 
tioning with glycogen depletion before sustained is- 
chemia, and with the attenuation of intracellular 
acidosis during ischemia. A longer period of precondi- 
tioning ischemia leads to glycogen depletion and a re- 
duction in infarct size, which are both described by an 
exponential declining curve [5]. However, the hypoth- 
esis that diminished glycogen stores per se limit gly- 
colysis, catabolite accumulation, and cell damage is 
not supported by other results: Myocardial glycogen 
loading induced by fasting improves the functional re- 
covery of ischemic rat hearts [43], and in a retrospec- 
tive study the preischemic glycogen content of rat 
hearts was correlated with the time of day but not 
postischemic functional recovery [4]. The question re- 
mains as to whether educed glycolytic flux and accu- 
mulated glycolytic products mediate or are secondary 
to preconditioning, but we do not believe that either 
lactate or proton accumulation is important in this re- 
spect. 
Glycolysis and adenosine 
Since adenosine has been implicated in ischemic pre- 
conditioning, anumber of authors have studied its role 
on glycolytic flux. Various groups [22,60] have shown 
that by binding to the Al-receptor , adenosine in- 
creases glycolytic flux and induces cardioprotection in 
isolated rabbit and rat hearts subjected to ischemia 
and hypoxia, respectively, whereas others have found 
that it reduces glycolysis and improves functional re- 
covery after ischemia in isolated working rat hearts 
perfused with glucose and palmitate [14,15]. These di- 
vergent results could be due to the models studied 
(low-flow vs. no-flow ischemia), the use of different 
substrates (glucose vs. glucose/fatty acids), and/or 
differences between species. 
Species Differences 
Although several groups have shown that the rat 
heart behaves differently from the hearts of other spe- 
cies, the isolated, perfused rat-heart model is quite 
often used to study preconditioning. It is generally 
believed that endogenous adenosine does not mediate 
preconditioning in this species but, as recently pointed 
out by Headrick [19], the relatively high adenosine 
levels in rat heart during preconditioning require an 
increase in (ant)agonist receptor concentration. We 
refer to the discussion by Przyklenk and Kloner [36] 
on the species (and model) dependency ofthe arrhyth- 
mic component. The same group [37] could not find 
any translocation of PKC after ischemic precondi- 
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tioning, and this failure to reproduce the original ob- 
servation in rabbit heart [29] may have been due to 
species differences. 
Questions can be raised about he abundant use of 
inhibitors and activators (often declared to be specific 
or selective on rather shaky grounds) to probe the 
proteins involved. The involvement of KAT P channels 
in the preconditioning of larger animals seems clear 
but may not be essential in rabbits and rats [for re- 
view, see [24]. A pertussis toxin-sensitive G-protein 
may play a central role in ischemic preconditioning 
across a broad range of species [20], but major differ- 
ences may exist in relation to the role of protein kinase 
C [16]. The involvement of the inhibitory G-protein in 
the arrhythmic omponent of preconditioning is also 
controversial. Nevertheless, ome of these discrepan- 
cies may be due to the details of the experimental 
models tudied [20]. 
Ev idence  fo r  P recond i t ion ing  
in Human Hear t  
Preinfarction angina 
Ischemic preconditioning clearly exists in many spe- 
cies, and possibly in humans. The phenomenon has 
been investigated during (retrospective) clinical stud- 
ies, coronary angioplasty, cardiac surgery, and in 
vitro. In recent clinical trials, it has been found that 
preinfarction angina seems to decrease creatine- 
kinase release, in-hospital deaths, arrhythmias, left- 
ventricular function, and infarct size [3,36]. Ottani et 
al. [35] used ventriculographically obtained regional 
wall motion as a means of indirectly determining in- 
farct size and found that this was less in patients with 
prodromal angina pectoris occurring at rest 24 hours 
before the infarct than in patients without previous 
angina, although the two groups had the same area at 
risk and in both collaterals were absent. However, as 
indicated in a recent review by Andreotti et al. [2], 
controversies still exist that might be explained by 
the use of thrombolysis, the baseline characteristics 
of the study population, the presence of multivessel 
disease, infarcted area, collaterals, and the period(s) 
of angina before infarction. For instance, studies in 
the period before the use of thrombolytics have shown 
that preinfarction angina has negative ffects [10], a 
finding that correlates with the observation that pre- 
conditioning exerts an effect only if reperfusion takes 
place within a certain time frame. Andreotti et al. [2] 
partly explained these discrepancies by the different 
definitions of preinfarction angina used. Furthermore, 
in a prospective study, they [2] observed that the in- 
farct size-limiting effect of preinfarction angina was 
merely related to faster coronary thrombolysis. 
Percutaneous transluminal coronary 
angioplasty 
Deutsch et al. [13] claim that a 90-second coronary 
occlusion induces preconditioning in humans, basing 
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Fig. 2. Lactate and hypoxanthine r lease after coronary an- 
gioplasty. In 28 patients undergoing angioplasty of the left 
anterior descending coronary artery, arterial and coronary 
sinus blood samples were taken immediately after occlusions 
lasting 60-90 seconds. They were rapidly deproteinized with 
acid and were assayed enzymatically (lactate) or by HPLC 
(hypoxanthine). Arteriovenous differences are presented 
means ± SEM. 
their conclusions partly on the drop in lactate uptake 
in 7 out of 12 patients in whom electrophysiological 
changes during angioplasty were investigated. Jen- 
kins et al. [24] have pointed out that the pretreatment 
of patients with dipyridamole may potentiate the ef- 
fect of preconditioning by increasing myocardial den- 
osine levels. 
In a larger patient population (n = 28), we mea- 
sured the myocardial release of lactate and hypo- 
xanthine (an ATP catabolite) immediately after four 
balloon inflations lasting 60-90 seconds. The arterio- 
venous difference in both metabolites did not change 
significantly as a result of the repeated occlusions 
(Fig. 2). The biochemical markers used provided no 
evidence for preconditioning during coronary angio- 
plasty [11]. We believe that the angioplasty times of 
balloon inflations, often lasting less than 2 minutes, 
are insufficient to induce ischemic preconditioning in
humans [24]. In this respect, it is interesting to note 
that studies using balloon inflations lasting 2 minutes 
or more [9,47,48] have demonstrated improved toler- 
ance to myocardial ischemia fter repetitive coronary 
occlusions. The exception seems to be a study de- 
scribed later [7]. Further evidence that ischemic pre- 
conditioning occurs during angioplasty and is me- 
diated by adenosine Al-receptor activation and 
KAwp-channel opening has recently been obtained: 
Adenosine Al-receptor blockade by bamiphylline [48] 
and aminophylline [7], as well as the administration of
the selective KAwp-channel b ocker glibenclamide [47], 
prevent ischemic preconditioning occurring during re- 
petitive balloon occlusions. 
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Coronary artery bypass graft surgery 
During both normothermic and hypothermic ntermit- 
tent aortic crossclamping in coronary artery bypass 
graft surgery, the release of lactate and inorganic 
phosphate has been found to be greater during the 
first than during subsequent reperfusion periods [53]. 
Yellon's group was the first to report hat an ischemic 
preconditioning protocol slowed the rate of ATP 
depletion during 10 minutes of crossclamping fibrilla- 
tion [1], but less ATP depletion in preconditioned 
hearts gives only indirect evidence of myocardial pro- 
tection because ischemic ell damage and myocardial 
function were not reported. It should be noted that 
the amounts of creatine kinase-MB and lactate re- 
leased by the ischemic myocardium were no different 
between the groups, although there was a tendency 
to lower values in preconditioned hearts. The role of 
adenosine in ischemic preconditioning has also been 
studied in the setting of bypass surgery, and it has 
been found that its presurgery infusion improved in- 
traoperative and postoperative h modynamic function 
and reduced ischemic ell damage [28]. 
Isolated trabeculae and cultured myocytes 
Yellon's group [46,57] exposed human atrial trabecu- 
lae to 90 minute of hypoxic substrate-free superfusion, 
and demonstrated that preconditioning prior to the 
sustained ischemic period improved functional recov- 
ery. This preconditioning effect could be blocked by 
an adenosine Al-antagonist, a PKC antagonist, and 
a KAwp-channel blocker. An adenosine Al-agonist, a 
KAwp-channel opener, and a PKC activator mimicked 
the effect of ischemic preconditioning, whereas the ef- 
fects of the KAwp-channel opener and the PKC activa- 
tor could be blocked by the KAwp-channel blocker gli- 
benclamide. Ikonomidis et al. [21] demonstrated that 
the infarct size-limiting effect of ischemic precondi- 
tioning also exists in human cultured ventricular 
cardiomyocytes. 
Discussion 
A number of endogenous compounds are candidate 
triggers of preconditioning: These are adenosine, bra- 
dykinin, and noradrenaline, which may work in con- 
junction to reach a threshold. Although we doubt the 
importance of catecholamines in this respect, we 
would like to point out that all of these metabolites 
activate intracellular signaling pathways via receptors 
linked to GTP-binding proteins and phospholipases; 
protein kinase(s) could be stimulated, and thus lead 
to the phosphorylation of putative target proteins 
[17]. As reviewed elsewhere in this issue [16], these 
include regulatory proteins of the KAT P channels and 
the expression of heat-shock proteins (for the second 
time window of protection), although, as outlined ear- 
lier, we do not believe that 5'-nucleotidase b longs to 
this class of possible targets. However, we do con- 
sider the possibility that the adenosine released ur- 
ing short periods of ischemia nd reperfusion activates 
PKC, which in turn phosphorylates a glycolytic key 
enzyme and thus increases glycolytic flux [23,60]. The 
present data do not allow any firm statement to be 
made regarding the preconditioning role of (the trans- 
location of) PKC in all species. Although there is 
growing evidence that the human heart can be precon- 
ditioned, there is still a lack of crucial information on 
the subcellular pathways involved (e.g., with PKC). 
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